PDF(Pubmed)
Abstract：
Objective: The price of pharmaceuticals is important from the economic and industrial perspectives but as well as patients\' access to treatment. This study aimed to analyze the variables affecting the prices of new drugs in South Korea\'s pricing system. Methods: Data on 192 new drugs listed in South Korea from 2012 to 2022 were collected from the official website of the Health Insurance Review and Assessment Service. The independent variables included drugs for severe diseases, alternatives, number of patients, number of advanced 7 countries listed, budget impact, and listing period. The dependent variables included annual treatment cost and the price ratio to the advanced 7 country\'s average adjusted price. Descriptive statistics of variables, linear correlations between quantitative independent and dependent variables, and associations between independent and dependent variables were analyzed. Results: The mean annual treatment cost and price ratio to the advanced 7 country\'s average adjusted price were higher for drugs for severe diseases and those with no alternatives. Annual treatment cost and price ratio to the advanced 7 country\'s average adjusted price were negatively correlated with the number of patients and positively correlated with the number of advanced 7 countries listed. Annual treatment cost was affected by the variables drugs for severe diseases, alternatives, number of patients, number of advanced 7 countries listed, and budget impact. The price ratio to the advanced 7 country\'s average adjusted price was affected by drugs for severe diseases, alternatives, and the number of patients. Conclusion: This study revealed the effect of different variables on the prices of new drugs in South Korea, allowing for the development of a more effective assessment system to evaluate the prices of new drugs while ensuring profitability for pharmaceutical companies, sustainability of public insurance, and accessibility to drugs by patients.
摘要：
目标：从经济和工业的角度来看，药品的价格很重要，而且对患者获得治疗也很重要。本研究旨在分析韩国定价体系中影响新药价格的变量。方法:从健康保险审查和评估服务官方网站收集2012-2022年在韩国上市的192种新药的数据。独立变量包括治疗严重疾病的药物，替代品，患者数量,列出的7个先进国家的数量，预算影响，和上市期。因变量包括年度治疗费用和价格比先进7国家的平均调整价格。变量的描述性统计，定量自变量和因变量之间的线性关系，并分析了自变量和因变量之间的关联。结果：对于严重疾病和没有替代品的药物，平均年治疗费用和价格比与先进的7个国家的平均调整价格较高。年治疗费用和价格比对先进7个国家的平均调整价格与患者人数呈负相关，与列出的先进7个国家的数量呈正相关。年度治疗费用受严重疾病可变药物的影响，替代品，患者数量,列出的7个先进国家的数量，和预算影响。价格比先进7国家的平均调整价格受到严重疾病药物的影响，替代品，以及患者的数量。结论:本研究揭示了不同变量对韩国新药价格的影响,允许开发更有效的评估系统来评估新药的价格，同时确保制药公司的盈利能力，公共保险的可持续性，以及患者对药物的可及性。
